Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo

International Immunopharmacology

Volumn 5, Issue 2, 2005, Pages 281-288

  Yoshimoto, Yuya ^a   Kawada, Manabu ^a   Ikeda, Daishiro ^a   Ishizuka, Masaaki ^a  

^a Numazu Bio Medical Research Institute   (Japan)

Author keywords

Adriamycin; Chemotherapy; Fas; Fas ligand; Tumor immunity

Indexed keywords

DOXORUBICIN; FAS LIGAND;

ANIMAL MODEL; ARTICLE; CELL COUNT; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; IMMUNITY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REDUCTION; SOLID TUMOR; SPLEEN CELL; SURFACE PROPERTY; WILD TYPE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD95; APOPTOSIS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; DOXORUBICIN; FAS LIGAND PROTEIN; FEMALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 12344274560     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2004.09.032     Document Type: Article

References (26)

1. S. Nagata, and P. Golstein The Fas death factor Science 267 1995 1449 1456
2. S. Nagata Apoptosis by death factor Cell 88 1997 355 365
3. R. Koomagi, and M. Volm Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance Int. J. Cancer 84 1999 239 243
4. M. Mottolese, S. Buglioni, C. Bracalenti, M.A. Cardarelli, L. Ciabocco, and D. Giannarelli Prognostic relevance of altered Fas (CD95)-system in human breast cancer Int. J. Cancer 89 2000 127 132
5. M. Shibakita, M. Tachibana, D.K. Dhar, T. Kotoh, S. Kinugasa, and H. Kubota Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer Clin. Cancer Res. 5 1999 2464 2469
6. N. Seki, A.D. Brooks, C.R. Carter, T.C. Back, E.M. Parsoneault, and M.J. Smyth Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin J. Immunol. 168 2002 3484 3492
7. D. Rosen, J.H. Li, S. Keidar, I. Markon, R. Orda, and G. Berke Tumor immunity in perforin-deficient mice: a role for CD95 (Fas/APO-1) J. Immunol. 164 2000 3229 3235
8. J.K. Lee, T.J. Sayers, A.D. Brooks, T.C. Back, H.A. Young, and K.L. Komschlies IFN-γ-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells J. Immunol. 164 2000 231 239
9. O. Micheau, E. Solary, A. Hammann, F. Martin, and MT. Dimanche-Boitrel Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity J. Natl. Cancer Inst. 89 1997 783 789
10. X.X. Wu, Y. Mizutani, Y. Kakehi, O. Yoshida, and O. Ogawa Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin Cancer Res. 60 2000 2912 2918
11. M. Muller, S. Wilder, D. Bannasch, D. Israeli, K. Lehlbach, and M. Li-Weber p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs J. Exp. Med. 188 1998 2033 2045
12. T. Kataoka, M. Ito, R.C. Budd, J. Tschopp, and K. Nagai Expression level of c-FLIP versus Fas determines susceptibility to Fas ligand-induced cell death in murine thymoma EL-4 cells Exp. Cell Res. 273 2002 256 264
13. T. Takahashi, M. Tanaka, C.I. Brannan, N.A. Jenkins, N.G. Copeland, and T. Suda Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand Cell 76 1994 969 976
14. R. Watanabe-Fukunaga, C.I. Brannan, N.G. Copeland, N.A. Jenkins, and S. Nagata Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis Nature 356 1992 314 317
15. M. Hosokawa, Y. Sawamura, T. Morikage, F. Okada, Z.Y. Xu, and K. Morikawa Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide Cancer Immunol. Immunother. 26 1988 250 256
16. M. Hosokawa, and H. Kobayashi Augmentation of antitumor immunity in cancer chemotherapy Gan To Kagaku Ryoho 17 1990 1402 1406
17. S.T. Eichhorst, S. Muerkoster, M.A. Weigand, and P.H. Krammer The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system Cancer Res. 61 2001 243 248
18. M. Adachi, S. Suematsu, T. Kondo, J. Ogasawara, T. Tanaka, and N. Yoshida Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver Nat. Genet. 11 1995 294 300
19. P.L. Cohen, and R.A. Eisenberg Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease Annu. Rev. Immunol. 9 1991 243 269
20. S. Nagata, and T. Suda Fas and Fas ligand: lpr and gld mutations Immunol. Today 16 1995 39 43
21. C. Friesen, I. Herr, P.H. Krammer, and K.M. Debatin Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells Nat. Med. 2 1996 574 577
22. S. Fulda, S.A. Susin, G. Kroemer, and K.M. Debatin Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells Cancer Res. 58 1998 4453 4460
23. N. Mitsiades, W.H. Yu, V. Poulaki, M. Tsokos, and I. Stamenkovic Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity Cancer Res. 61 2001 577 581
24. Y. Kalechman, G. Strassmann, M. Albeck, and B. Sredni Up-regulation by ammonium trichloro(dioxoethylene-0,0′) tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101 J. Immunol. 161 1998 3536 3542
25. S. Nakamori, M. Tujie, Y. Takahashi, S. Maruhashi, A. Miyamoto, and H. Nagano Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer Gan To Kagaku Ryoho 31 2004 51 54
26. Y. Takahashi, H. Kitakata, K. Yamashita, K. Yasumoto, K. Omote, and T. Minamoto Pilot study of low-dose, divided maximum tolerated dose of CPT-11 in 21 consecutive patients with metastatic colorectal or gastric cancer Surg. Today 34 2004 246 250